Advanced or metastatic renal cell carcinoma (RCC) responds poorly to current combination therapies, as anti-angiogenic agents and immune checkpoint inhibitors fail to act in a spatiotemporally synchronized manner. Consequently, their...
Wang et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: